Mirum Pharmaceuticals is at an inflection point. The company's sales are growing fast, led by the success of Livmarli. Mirum has multiple potential catalysts on the way in 2026. In several important ...
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced the appointment of Joanne Quan, MD as Chief Medical Officer. Dr. Quan will lead the global clinical ...
Management forecasted positive cash flow resumption in 2027, following the temporary R&D spike related to regulatory filings and manufacturing scale-up. CEO Peetz stated, "we have now built a ...
Mirum Pharmaceuticals’ MIRM lead product, Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) inhibitor, is approved for the treatment of cholestatic pruritus in ...
- 2026 expected global net product sales of $630 million to $650 million - Volixibat VISTAS study in PSC topline data expected Q2 2026 - LIVMARLI ® EXPAND study in additional cholestatic pruritus ...
Mirum Pharmaceuticals (MIRM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jonathan Wolleben from JMP Securities remains neutral on the stock ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM) today announced the pricing of its offering of $275.0 million aggregate principal amount of 4.00% convertible ...
Mirum Pharmaceuticals stock has risen nearly 25% since my 'Sell' rating in October, prompting a re-evaluation of the company's performance and prospects. Mirum markets three drugs: LIVMARLI, Cholbam, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results